Perspectives on the clinical development of immunotherapy in prostate cancer / 亚洲男科学杂志(英文版)
Asian Journal of Andrology
;
(6): 253-259, 2018.
Artigo
em Inglês
| WPRIM
| ID: wpr-1009596
ABSTRACT
Despite impressive survival benefits with immunotherapy in patients with various solid tumors, the full potential of these agents in prostate cancer has yet to be realized. Sipuleucel-T demonstrated a survival benefit in this population, indicating that prostate cancer is an immunoresponsive disease; however, these results have not been matched by other agents. A large trial with ipilimumab in prostate cancer failed to meet its primary objective, and small trials with PD-1/PD-L1 inhibitors did not yield a significant improvement in overall response. However, several late-stage clinical trials are underway with other vaccines in prostate cancer. Reports of clinical benefit with immunotherapies, particularly when used in combination or a select population, have provided the framework to develop sound clinical trials. Understanding immunogenic modulation, antigen spread, biomarkers, and DNA-repair defects will also help mold future strategies. Through rational patient selection and evidence-based combination approaches, patients with prostate cancer may soon derive durable survival benefits with immunotherapies.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Feniltioidantoína
/
Neoplasias da Próstata
/
Extratos de Tecidos
/
Benzamidas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Vacinas Anticâncer
/
Antígeno B7-H1
/
Antígeno CTLA-4
/
Receptor de Morte Celular Programada 1
/
Ipilimumab
Limite:
Animais
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Asian Journal of Andrology
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS